MMP25

Summary

MMP25 (matrix metallopeptidase 25, HGNC:14246) is a protein-coding gene on chromosome 16p13.3, encoding Matrix metalloproteinase-25 (Q9NPA2). May activate progelatinase A.

Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMPs are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. However, the protein encoded by this gene is a member of the membrane-type MMP (MT-MMP) subfamily, attached to the plasma membrane via a glycosylphosphatidyl inositol anchor. In response to bacterial infection or inflammation, the encoded protein is thought to inactivate alpha-1 proteinase inhibitor, a major tissue protectant against proteolytic enzymes released by activated neutrophils, facilitating the transendothelial migration of neutrophils to inflammatory sites. The encoded protein may also play a role in tumor invasion and metastasis through activation of MMP2. The gene has previously been referred to as MMP20 but has been renamed MMP25.

Source: NCBI Gene 64386 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 132 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_022468

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14246
Approved symbol	MMP25
Name	matrix metallopeptidase 25
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	MT6-MMP
Ensembl gene	ENSG00000008516
Ensembl biotype	protein_coding
OMIM	608482
Entrez	64386

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 4 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000336577, ENST00000570755, ENST00000575441, ENST00000612971, ENST00000850602, ENST00000928200, ENST00000928201

RefSeq mRNA: 1 — MANE Select: NM_022468 NM_022468

CCDS: CCDS10492

Canonical transcript exons

ENST00000336577 — 10 exons

Exon	Start	End
ENSE00000665807	3057033	3057209
ENSE00000665925	3058412	3058669
ENSE00001195368	3058181	3058333
ENSE00001432733	3058827	3060726
ENSE00001733155	3047415	3047547
ENSE00002289075	3046561	3047016
ENSE00003474037	3050254	3050546
ENSE00003568956	3057531	3057613
ENSE00003611892	3057310	3057394
ENSE00003688042	3050009	3050144

Expression profiles

Bgee: expression breadth ubiquitous, 217 present calls, max score 97.39.

FANTOM5 (CAGE): breadth broad, TPM avg 6.8098 / max 2291.8810, expressed in 404 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
152370	4.2470	330
152371	0.8636	104
152373	0.6547	56
152369	0.5368	76
152368	0.2897	39
152372	0.1060	23
152378	0.0354	6
152375	0.0341	10
152377	0.0232	7
152376	0.0194	9

Top tissues by expression

266 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	97.39	gold quality
spleen	UBERON:0002106	94.07	gold quality
granulocyte	CL:0000094	94.02	gold quality
type B pancreatic cell	CL:0000169	91.63	silver quality
diaphragm	UBERON:0001103	91.08	silver quality
vena cava	UBERON:0004087	90.87	silver quality
olfactory bulb	UBERON:0002264	89.95	silver quality
cervix squamous epithelium	UBERON:0006922	87.67	silver quality
male germ cell	CL:0000015	87.49	silver quality
sperm	CL:0000019	87.13	silver quality
periodontal ligament	UBERON:0008266	86.96	gold quality
vermiform appendix	UBERON:0001154	86.01	gold quality
caecum	UBERON:0001153	85.99	gold quality
body of tongue	UBERON:0011876	85.70	silver quality
pharyngeal mucosa	UBERON:0000355	85.60	silver quality
cervix epithelium	UBERON:0004801	85.13	silver quality
bone marrow	UBERON:0002371	85.00	gold quality
tongue squamous epithelium	UBERON:0006919	84.94	silver quality
upper lobe of left lung	UBERON:0008952	84.92	gold quality
bone marrow cell	CL:0002092	84.62	gold quality
cardia of stomach	UBERON:0001162	84.35	silver quality
nipple	UBERON:0002030	84.24	gold quality
paraflocculus	UBERON:0005351	84.17	gold quality
mucosa of urinary bladder	UBERON:0001259	84.16	silver quality
cerebellar vermis	UBERON:0004720	84.06	silver quality
right lung	UBERON:0002167	83.95	gold quality
pons	UBERON:0000988	83.88	silver quality
upper arm skin	UBERON:0004263	83.83	silver quality
pancreatic ductal cell	CL:0002079	83.77	silver quality
tongue	UBERON:0001723	83.72	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.97

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting MMP25, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-23A-5P	99.94	65.39	468
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-3606-3P	99.11	69.84	3254
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-4738-3P	98.98	67.98	1846
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-5187-5P	98.54	67.94	952
HSA-MIR-6852-3P	98.54	67.60	1468

Literature-anchored findings (GeneRIF, showing 12)

• MMP25 is regulated by clusterin in vivo (PMID:12860995)
• MT6-MMP may play a role in colon cancer and exhibit unique biochemical and structural properties that may regulate proteolytic function at the cell surface. (PMID:17513868)
• the stem region of MT6-MMP is the dimerization interface, an event whose outcome imparts protease stability to the protein (PMID:18936094)
• MMP-25 plays an important role in multiple sclerosis pathology (PMID:19726693)
• Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase. (PMID:20308072)
• individuals with history of chronic airways inflammation (asthma and COPD) serum leukolysin may be a metabolic marker associated with chronic atopy-associated respiratory inflammation. (PMID:20337648)
• MT6-MMP is present in the membrane, granules and nuclear/endoplasmic reticulum/Golgi fractions of PMNs where it is displayed as a disulfide-linked homodimer of 120 kDa (PMID:20501611)
• MT6-MMP regulates neutrophil and monocyte chemotaxis and by generating “eat-me” signals upon vimentin cleavage potentially increases phagocytic removal of neutrophils to resolve inflammation. (PMID:22367194)
• IL-2-upregulated MT6 cell-surface expression correlates with CD16 downmodulation. MT6, sequestered in intracellular compartments in unstimulated NK cells, translocates to the effector-target cell interface of CD16-mediated immunological synapses. (PMID:23851692)
• In absolute mRNA levels, significant differences were found in expression of MMP2, MMP24, and MMP25 in gastric carcinoma compared with superficial gastritis. (PMID:24669030)
• Association of MMP3, MMP14, and MMP25 gene polymorphisms with cerebral stroke risk: a case-control study. (PMID:37986083)
• Elevated Plasma Levels of MT4-MMP and MT6-MMP; A New Observation in Patients with Thyroid Nodules. (PMID:38310435)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	mmp17b	ENSDARG00000102956
mus_musculus	Mmp25	ENSMUSG00000023903
rattus_norvegicus	Mmp25	ENSRNOG00000071032
caenorhabditis_elegans		WBGENE00010524
caenorhabditis_elegans		WBGENE00012185
caenorhabditis_elegans		WBGENE00012364
caenorhabditis_elegans		WBGENE00016283
caenorhabditis_elegans		WBGENE00194737

Paralogs (23): MMP2 (ENSG00000087245), MMP11 (ENSG00000099953), MMP9 (ENSG00000100985), MMP15 (ENSG00000102996), HPX (ENSG00000110169), MMP8 (ENSG00000118113), MMP19 (ENSG00000123342), MMP24 (ENSG00000125966), MMP7 (ENSG00000137673), MMP20 (ENSG00000137674), MMP27 (ENSG00000137675), MMP13 (ENSG00000137745), MMP3 (ENSG00000149968), MMP21 (ENSG00000154485), MMP16 (ENSG00000156103), MMP14 (ENSG00000157227), MMP10 (ENSG00000166670), MMP26 (ENSG00000167346), MMP23B (ENSG00000189409), MMP1 (ENSG00000196611), MMP17 (ENSG00000198598), MMP12 (ENSG00000262406), MMP28 (ENSG00000271447)

Protein

Protein identifiers

Matrix metalloproteinase-25 — Q9NPA2 (reviewed: Q9NPA2)

Alternative names: Leukolysin, Membrane-type matrix metalloproteinase 6, Membrane-type-6 matrix metalloproteinase

All UniProt accessions (2): Q9NPA2, A0A087WZS5

UniProt curated annotations — full annotation on UniProt →

Function. May activate progelatinase A.

Subcellular location. Cell membrane. Secreted. Extracellular space. Extracellular matrix.

Tissue specificity. Expressed predominantly in leukocytes, lung and spleen. Expressed also in colon carcinoma, astrocytoma and glioblastomas.

Post-translational modifications. The precursor is cleaved by a furin endopeptidase.

Cofactor. Binds 1 zinc ion per subunit.

Domain organisation. The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.

Similarity. Belongs to the peptidase M10A family.

RefSeq proteins (1): NP_071913* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000585	Hemopexin-like_dom	Domain
IPR001818	Pept_M10_metallopeptidase	Domain
IPR002477	Peptidoglycan-bd-like	Domain
IPR006026	Peptidase_Metallo	Domain
IPR018487	Hemopexin-like_repeat	Repeat
IPR021190	Pept_M10A	Family
IPR024079	MetalloPept_cat_dom_sf	Homologous_superfamily
IPR033739	M10A_MMP	Domain
IPR036375	Hemopexin-like_dom_sf	Homologous_superfamily

Pfam: PF00045, PF00413, PF01471

UniProt features (20 total): binding site 4, repeat 4, propeptide 2, region of interest 2, signal peptide 1, short sequence motif 1, compositionally biased region 1, active site 1, lipid moiety-binding region 1, disulfide bond 1, sequence conflict 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NPA2-F1	78.88	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 234

Ligand- & substrate-binding residues (4): 90 (in inhibited form); 233; 237; 243

Post-translational modifications (1): 539

Disulfide bonds (1): 317–508

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-1592389	Activation of Matrix Metalloproteinases
R-HSA-6798695	Neutrophil degranulation
R-HSA-1474228	Degradation of the extracellular matrix
R-HSA-1474244	Extracellular matrix organization
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 243 (showing top): MORF_RAGE, REACTOME_INNATE_IMMUNE_SYSTEM, GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_INFLAMMATORY_RESPONSE, GOCC_SECRETORY_GRANULE, chr11q22, MODULE_418, GOZGIT_ESR1_TARGETS_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_TOOTH_MINERALIZATION, SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_DN, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_ENAMEL_MINERALIZATION, MODULE_99, TGANTCA_AP1_C

GO Biological Process (5): proteolysis (GO:0006508), inflammatory response (GO:0006954), extracellular matrix organization (GO:0030198), collagen catabolic process (GO:0030574), hard palate development (GO:0060022)

GO Molecular Function (7): metalloendopeptidase activity (GO:0004222), zinc ion binding (GO:0008270), protein binding (GO:0005515), peptidase activity (GO:0008233), metallopeptidase activity (GO:0008237), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (7): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), membrane (GO:0016020), extracellular matrix (GO:0031012), specific granule membrane (GO:0035579), side of membrane (GO:0098552), extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Degradation of the extracellular matrix	1
Innate Immune System	1
Extracellular matrix organization	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
membrane	2
protein metabolic process	1
defense response	1
extracellular structure organization	1
external encapsulating structure organization	1
catabolic process	1
collagen metabolic process	1
anatomical structure development	1
secondary palate development	1
endopeptidase activity	1
metallopeptidase activity	1
transition metal ion binding	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
cation binding	1
cell periphery	1
external encapsulating structure	1
secretory granule membrane	1
specific granule	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

934 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MMP25	KLK4	Q9Y5K2	804
MMP25	HPX	P02790	786
MMP25	ENAM	Q9NRM1	717
MMP25	CNNM4	Q6P4Q7	675
MMP25	AMELX	Q99217	664
MMP25	AMBN	Q9NP70	662
MMP25	FURIN	P09958	655
MMP25	TIMP1	P01033	651
MMP25	ODAPH	Q17RF5	606
MMP25	WDR72	Q3MJ13	583
MMP25	SACK1H	Q6ZRV2	582
MMP25	AMTN	Q6UX39	546
MMP25	TIMP2	P16035	523
MMP25	FN1	P02751	511
MMP25	MMP8	P22894	498

IntAct

7 interactions, top by confidence:

A	B	Type	Score
MEOX2	MMP25	psi-mi:“MI:0915”(physical association)	0.560
FCN1	MMP25	psi-mi:“MI:0915”(physical association)	0.370
CD177	MYO1G	psi-mi:“MI:0914”(association)	0.350
MMP25	MEOX2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (13): PIK3R2 (Negative Genetic), MMP25 (Negative Genetic), PRKCZ (Negative Genetic), MMP25 (Negative Genetic), MMP25 (Negative Genetic), XIAP (Positive Genetic), CLU (Affinity Capture-Western), MEOX2 (Two-hybrid), MMP25 (Affinity Capture-RNA), MMP25 (Negative Genetic), MMP8 (Negative Genetic), MMP25 (Negative Genetic), MMP25 (Affinity Capture-RNA)

ESM2 similar proteins: A6NE02, A8MY62, A8T672, A8T677, A8T695, C9JR72, D3Z7H8, O08644, O15197, O19179, O62763, O94766, P0C0K6, P0C0K7, P21836, P22303, P24347, P35475, P50427, P51839, P51840, P52785, P54760, P55203, Q01634, Q02846, Q04912, Q29499, Q2KHV9, Q2T9T9, Q3UH93, Q5JZY3, Q69ZQ1, Q6NSJ0, Q6ZPS2, Q80W65, Q8BH02, Q8BYG9, Q8CG64, Q8IUL8

Diamond homologs: D0EM77, G5EBU3, O04529, O13065, O18733, O18767, O18927, O23507, O35548, O44836, O54732, O55123, O55761, O60882, O62806, O70138, O75900, O77656, O88272, O88676, O88766, O93470, P03956, P03957, P07152, P08253, P08254, P09237, P09238, P13943, P14780, P21692, P22757, P22894, P23097, P24347, P28053, P28862, P28863, P29136

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
MMP25	“up-regulates activity”	MMP2	cleavage
MMP25	up-regulates	ECM_disassembly
MMP25	down-regulates	ECM

Disease & clinical

Clinical variants and AI predictions

ClinVar

132 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	122
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3393 predictions. Top by Δscore:

Variant	Effect	Δscore
11:102579032:CACTT:C	donor_loss	1.0000
11:102579033:ACTTA:A	donor_loss	1.0000
11:102579034:CTTA:C	donor_loss	1.0000
11:102579035:TTA:T	donor_loss	1.0000
11:102579036:TA:T	donor_loss	1.0000
11:102579037:A:AC	donor_gain	1.0000
11:102579037:AC:A	donor_gain	1.0000
11:102579038:C:CC	donor_gain	1.0000
11:102579038:CC:C	donor_gain	1.0000
11:102579038:CCA:C	donor_gain	1.0000
11:102579138:CGTAG:C	acceptor_gain	1.0000
11:102579140:TAG:T	acceptor_gain	1.0000
11:102579143:C:CC	acceptor_gain	1.0000
11:102593433:CCATA:C	donor_loss	1.0000
11:102593434:CATA:C	donor_loss	1.0000
11:102593435:ATACC:A	donor_loss	1.0000
11:102593436:TACC:T	donor_loss	1.0000
11:102593437:A:AC	donor_gain	1.0000
11:102593437:A:AG	donor_loss	1.0000
11:102593438:C:CC	donor_gain	1.0000
11:102593438:C:CT	donor_loss	1.0000
11:102593591:GGGAC:G	acceptor_gain	1.0000
11:102593592:GGAC:G	acceptor_gain	1.0000
11:102593593:GAC:G	acceptor_gain	1.0000
11:102593594:AC:A	acceptor_gain	1.0000
11:102593594:ACC:A	acceptor_loss	1.0000
11:102593595:CC:C	acceptor_gain	1.0000
11:102593596:C:CC	acceptor_gain	1.0000
11:102593596:C:T	acceptor_gain	1.0000
11:102594615:GGGTA:G	donor_loss	1.0000

AlphaMissense

3619 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:3050438:T:C	F185L	0.999
16:3050440:C:A	F185L	0.999
16:3050440:C:G	F185L	0.999
16:3047513:G:C	Q66H	0.998
16:3047513:G:T	Q66H	0.998
16:3050044:T:C	C90R	0.998
16:3050045:G:A	C90Y	0.998
16:3050046:C:G	C90W	0.998
16:3050439:T:G	F185C	0.998
16:3050471:T:C	F196L	0.998
16:3050473:C:A	F196L	0.998
16:3050473:C:G	F196L	0.998
16:3050511:T:C	F209S	0.998
16:3050528:T:A	W215R	0.998
16:3050528:T:C	W215R	0.998
16:3050530:G:C	W215C	0.998
16:3050530:G:T	W215C	0.998
16:3057062:G:C	A231P	0.998
16:3057068:C:G	H233D	0.998
16:3057078:G:A	G236D	0.998
16:3057080:C:G	H237D	0.998
16:3057082:C:A	H237Q	0.998
16:3057082:C:G	H237Q	0.998
16:3057100:C:A	H243Q	0.998
16:3057100:C:G	H243Q	0.998
16:3057124:G:A	M251I	0.998
16:3057124:G:C	M251I	0.998
16:3057124:G:T	M251I	0.998
16:3058254:G:C	W360C	0.998
16:3058254:G:T	W360C	0.998

dbSNP variants (sampled 300 via entrez): RS1000020951 (16:3045319 G>A), RS1000310751 (16:3059135 G>T), RS1000333071 (16:3046663 C>A,G,T), RS1000506108 (16:3050775 G>A,C), RS1000809057 (16:3059826 G>A,C), RS1000831633 (16:3050831 G>A), RS1000861616 (16:3060052 A>C), RS1000888053 (16:3060148 C>A), RS1001018470 (16:3046421 C>A), RS1001083287 (16:3055765 C>T), RS1001112200 (16:3051154 A>C), RS1001336864 (16:3059986 T>C,G), RS1001410892 (16:3046287 C>G,T), RS1001671989 (16:3045983 G>A), RS1001724472 (16:3046119 G>T)

Disease associations

OMIM: gene MIM:608482 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (1): Orofacial clefting syndrome (Orphanet:139039)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1795103 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 29,447 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL279785	MARIMASTAT	3	29,447

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — M10: Matrix metallopeptidase

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
CGS-27023A	Inhibition	8.82	pIC50

ChEMBL bioactivities

9 potent at pChembl≥5 of 9 total, top 9 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.82	IC50	1.5	nM	CGS-27023A
8.47	IC50	3.4	nM	CHEMBL1795862
7.47	IC50	34	nM	CHEMBL1795351
7.42	IC50	38	nM	CHEMBL1795857
7.12	IC50	76	nM	CHEMBL1795859
6.77	IC50	170	nM	CHEMBL1795861
6.66	IC50	220	nM	CHEMBL1795860
6.47	IC50	340	nM	CHEMBL1795858
5.00	IC50	1e+04	nM	MARIMASTAT

PubChem BioAssay actives

11 with measured affinity, of 13 total; 11 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide;hydrochloride	603762: Inhibition of human MMP25 by fluorometric assay	ic50	0.0015	uM
(3R)-2-[5-[2-(4-butylphenyl)ethynyl]thiophen-2-yl]sulfonyl-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	603762: Inhibition of human MMP25 by fluorometric assay	ic50	0.0034	uM
2-[[5-[2-(4-butylphenyl)ethynyl]thiophen-2-yl]sulfonylamino]-N-hydroxyacetamide	603762: Inhibition of human MMP25 by fluorometric assay	ic50	0.0340	uM
(2R)-2-[[5-[2-(4-butylphenyl)ethynyl]thiophen-2-yl]sulfonylamino]-N-hydroxy-3-(4-phenylmethoxyphenyl)propanamide	603762: Inhibition of human MMP25 by fluorometric assay	ic50	0.0380	uM
(2R)-2-[[5-[2-(4-butylphenyl)ethynyl]thiophen-2-yl]sulfonylamino]-N-hydroxy-3-(1H-indol-3-yl)propanamide	603762: Inhibition of human MMP25 by fluorometric assay	ic50	0.0760	uM
(4R)-3-[5-[2-(4-butylphenyl)ethynyl]thiophen-2-yl]sulfonyl-N-hydroxy-1,3-thiazolidine-4-carboxamide	603762: Inhibition of human MMP25 by fluorometric assay	ic50	0.1700	uM
(2R)-3-(1-benzothiophen-3-yl)-2-[[5-[2-(4-butylphenyl)ethynyl]thiophen-2-yl]sulfonylamino]-N-hydroxypropanamide	603762: Inhibition of human MMP25 by fluorometric assay	ic50	0.2200	uM
(2R)-3-(4-benzoylphenyl)-2-[[5-[2-(4-butylphenyl)ethynyl]thiophen-2-yl]sulfonylamino]-N-hydroxypropanamide	603762: Inhibition of human MMP25 by fluorometric assay	ic50	0.3400	uM
3-(benzenesulfonyl)-N-hydroxypropanamide	1799784: Inhibition Assay from Article 10.1074/jbc.M110.107094: “Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.”	ic50	0.9000	uM
2-(4-ethoxyphenyl)-N-hydroxybenzamide	1799784: Inhibition Assay from Article 10.1074/jbc.M110.107094: “Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.”	ic50	2.5000	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’,3-dihydroxy-2-(2-methylpropyl)butanediamide	1274676: Inhibition of MMP25 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay	ic50	10.0000	uM

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	increases expression, affects cotreatment	2
Tretinoin	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
fluorene-9-bisphenol	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
sodium arsenite	increases expression	1
benzo(k)fluoranthene	decreases reaction, increases expression	1
vanadyl sulfate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
SB 203580	increases expression, decreases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Acetylcysteine	decreases reaction, increases expression	1
Air Pollutants	affects expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	affects cotreatment, decreases expression	1
Copper	affects binding, increases expression	1
Diuron	affects expression	1
Estradiol	affects cotreatment, increases expression	1
Hydralazine	affects cotreatment, increases expression	1
Ozone	affects expression, increases abundance	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

4 unique, capped per target: 4 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1069317	Binding	Inhibition of MMP25	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. — Bioorg Med Chem Lett

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SY69	HAP1 MMP25 (-) 1	Cancer cell line	Male
CVCL_SY70	HAP1 MMP25 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.